Paper26319004
Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing.
Henry KA and 2 others. Protein Eng Des Sel, 2015. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing. Papers, record 26319004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26319004
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cross Reactions | Major topic |
| High-Throughput Nucleotide Sequencing | Major topic |
| Sequence Analysis, DNA | Major topic |
| Serum Albumin | Major topic |
| Single-Domain Antibodies | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Rats |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42719415 | Development and Humanization of a Camelid-Derived Neutralizing Nanobody Targeting Botulinum Neurotoxin Type A. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42719415 | PubMed |
| 41870123 | Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/41870123 | PubMed |
| 39810248 | In vivo brain delivery of BBB-enabled iduronate 2-sulfatase in rats. | Fluids Barriers CNS | 2025 | https://conductscience.org/library/papers/39810248 | PubMed |
| 38590528 | Generation and characterization of antagonistic anti-human CD39 nanobodies. | Front Immunol | 2024 | https://conductscience.org/library/papers/38590528 | PubMed |
| 37679618 | Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries. | Methods Mol Biol | 2023 | https://conductscience.org/library/papers/37679618 | PubMed |
| 37349546 | Cross-reactivity trends when selecting scFv antibodies against snake toxins using a phage display-based cross-panning strategy. | Sci Rep | 2023 | https://conductscience.org/library/papers/37349546 | PubMed |
| 36754285 | Nanobodies: Robust miniprotein binders in biomedicine. | Adv Drug Deliv Rev | 2023 | https://conductscience.org/library/papers/36754285 | PubMed |
| 35563400 | Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35563400 | PubMed |
| 32780549 | A guide to: generation and design of nanobodies. | FEBS J | 2021 | https://conductscience.org/library/papers/32780549 | PubMed |
| 31468301 | Advances in the Production and Batch Reformatting of Phage Antibody Libraries. | Mol Biotechnol | 2019 | https://conductscience.org/library/papers/31468301 | PubMed |
| 30972081 | Plant-Produced Chimeric VHH-sIgA Against Enterohemorrhagic E. coli Intimin Shows Cross-Serotype Inhibition of Bacterial Adhesion to Epithelial Cells. | Front Plant Sci | 2019 | https://conductscience.org/library/papers/30972081 | PubMed |
| 30656359 | Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct. | Immunogenetics | 2019 | https://conductscience.org/library/papers/30656359 | PubMed |
| 30540857 | Neutralization of Clostridium difficile toxin B with VHH-Fc fusions targeting the delivery and CROPs domains. | PLoS One | 2018 | https://conductscience.org/library/papers/30540857 | PubMed |
| 30518413 | Isolation and characterization of camelid single-domain antibodies against HER2. | BMC Res Notes | 2018 | https://conductscience.org/library/papers/30518413 | PubMed |
| 29420788 | Phage display peptide libraries: deviations from randomness and correctives. | Nucleic Acids Res | 2018 | https://conductscience.org/library/papers/29420788 | PubMed |
| 29375542 | Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries. | Front Immunol | 2017 | https://conductscience.org/library/papers/29375542 | PubMed |
| 29163485 | A Novel Affinity Tag, ABTAG, and Its Application to the Affinity Screening of Single-Domain Antibodies Selected by Phage Display. | Front Immunol | 2017 | https://conductscience.org/library/papers/29163485 | PubMed |
| 28443097 | Large Diversity of Functional Nanobodies from a Camelid Immune Library Revealed by an Alternative Analysis of Next-Generation Sequencing Data. | Front Immunol | 2017 | https://conductscience.org/library/papers/28443097 | PubMed |
| 27631624 | A Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain Antibodies. | PLoS One | 2016 | https://conductscience.org/library/papers/27631624 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26319004
GET https://conductscience.org/api/papers/v1/26319004/authors